Treatment of atopic dermatitis using non-thermal atmospheric plasma in an animal model

Sci Rep. 2021 Aug 9;11(1):16091. doi: 10.1038/s41598-021-95471-z.

Abstract

Cold atmospheric plasma (CAP) has been incorporated into various fields, including promotion of cutaneous wound healing. Atopic dermatitis (AD) is a chronic cutaneous condition characterized by inflammation-induced skin wounds and impaired skin barrier function. To investigate whether CAP may improve AD using an animal model. Dermatophagoides farinae extracts (DFE)-induced murine models of AD were used in this study. The plasma-treated group received a total of 6 CAP treatments during 2 weeks, while the control group did not receive any treatment. Differences in dermatitis severity, transepidermal water loss (TEWL), serum level of immunoglobulin (Ig) E and epidermal thickness were evaluated in both groups. The dermatitis severity was significantly improved by CAP treatment. TEWL was lower in the plasma-treated group compared with the non-treated control group. Serum Ig E dropped significantly after treatment with CAP. Difference in epidermal thickness of the ear skin was not significant between the plasma-treated and non-treated groups. Localized treatment of AD with CAP decreases dermatitis severity, TEWL, and serum Ig E level. These results show CAP's potentials as a novel therapeutic modality for AD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Dermatitis, Atopic / immunology*
  • Dermatitis, Atopic / therapy*
  • Dermatophagoides farinae / immunology
  • Disease Models, Animal
  • Epidermis / immunology
  • Immunoglobulin E / immunology
  • Inflammation / immunology
  • Inflammation / therapy
  • Male
  • Mice
  • Skin / immunology

Substances

  • Immunoglobulin E